REG - C4X Discovery - C4X Discovery receives Sanofi milestone payment

C4X Discovery HoldingsAnnouncement

06/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220706:nRSF4373Ra&default-theme=true

RNS Number : 4373R  C4X Discovery Holdings PLC  06 July 2022

C4X Discovery Holdings plc

 

C4X Discovery receives first milestone payment from Sanofi

 

€3 million milestone payment triggered by pre-clinical progression in oral
IL-17A inhibitor programme

 

06 July 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces that it has received a milestone payment of
€3 million from Sanofi under the IL-17A Inhibitor programme license
agreement entered into in April 2021.

 

Under the terms of the deal, C4XD is entitled to up to a total of €414
million in upfront, pre-clinical, development, regulatory and
commercialisation milestone payments plus royalties on future net sales.

 

Clive Dix, CEO of C4X Discovery, said: "This first milestone payment is an
important step in demonstrating the value of C4XD's expertise and our unique
approach to drug discovery to deliver differentiated small molecules to the
pharmaceutical industry. We are delighted to be working with Sanofi to rapidly
drive the programme through this pre-clinical phase and we are confident that
our molecules have the potential to deliver future life-changing oral IL-17A
therapeutics for patients."

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700
 C4X Discovery Holdings

 

Notes to Editors:

 

About C4X Discovery

 

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCRAMBTMTTMTAT